Cyclerion Therapeutics (NASDAQ:KRSA) Shares Climb 5.2% – Still a Buy?

Cyclerion Therapeutics, Inc. (NASDAQ:KRSA – Get Free Report)’s stock price rose 5.2% during mid-day trading on Monday. The company traded as high as $33.42 and last traded at $33.30. 29,911 shares changed hands during trading, a decline of 89% from the average daily volume of 276,293 shares. The stock had previously closed at $31.65.

Wall Street Analyst Weigh In

KRSA has been the topic of several research analyst reports. Guggenheim started coverage on Cyclerion Therapeutics in a report on Monday, September 28th. They issued a “buy” rating and a $70.00 price objective on the stock. Stifel Nicolaus initiated coverage on shares of Cyclerion Therapeutics in a research report on Monday, September 14th. They set a “buy” rating and a $43.00 price target on the stock. UBS Group began coverage on shares of Cyclerion Therapeutics in a research note on Friday, September 11th. They set a “buy” rating and a $55.00 target price for the company. TD Cowen assumed coverage on Cyclerion Therapeutics in a research note on Monday, September 14th. They set a “buy” rating on the stock. Finally, Zacks Research upgraded shares of Cyclerion Therapeutics to a “hold” rating in a research note on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Cyclerion Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.20.

View Our Latest Analysis on Cyclerion Therapeutics

Cyclerion Therapeutics Trading Up 3.4%

The company has a market cap of $1.49 billion, a P/E ratio of -2.58 and a beta of 1.85. The stock has a fifty day moving average price of $32.07.

Cyclerion Therapeutics (NASDAQ:KRSA – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($3.19) EPS for the quarter, topping analysts’ consensus estimates of ($50.40) by $47.21. Analysts anticipate that Cyclerion Therapeutics, Inc. will post -5.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Cyclerion Therapeutics

A number of large investors have recently modified their holdings of KRSA. ADAR1 Capital Management LLC acquired a new position in shares of Cyclerion Therapeutics during the second quarter worth $1,013,000. Braidwell LP acquired a new position in shares of Cyclerion Therapeutics during the 2nd quarter worth about $532,000. Finally, BlackRock Inc. acquired a new position in shares of Cyclerion Therapeutics during the 2nd quarter worth about $57,000. 75.62% of the stock is owned by hedge funds and other institutional investors.

About Cyclerion Therapeutics

(Get Free Report)

Cyclerion Therapeutics was a clinical-stage biotechnology company focused on developing medicines for serious disorders of the central nervous system. The company originated as a spinout from Ironwood Pharmaceuticals in 2019 and was based in Cambridge, Massachusetts. Its research centered on small-molecule drugs that stimulate soluble guanylate cyclase, an enzyme involved in cellular signaling. Cyclerion’s development portfolio included zagociguat, an investigational, brain-penetrant candidate studied for conditions including cognitive impairment associated with Alzheimer’s disease and other neurological disorders.

Featured Stories

Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.